Screening for known mutations in EIF2B genes in a large panel of patients with premature ovarian failure

被引：38

作者：

Fogli A. ^{[1
]}

Gauthier-Barichard F. ^{[1
]}

Schiffmann R. ^{[2
]}

Vanderhoof V.H. ^{[3
]}

Bakalov V.K. ^{[3
]}

Nelson L.M. ^{[3
]}

Boespflug-Tanguy O. ^{[1
]}

机构：

[1] INSERM UMR 384, Faculté de Médecine, 63001 Clermont-Ferrand Cedex

[2] Devmtl./Metabolic Neurology Branch, National Institutes of Health, Bethesda, MD

[3] Natl. Inst. Child Health/Hum. Devmt., Bethesda, MD

来源：

BMC Women's Health | / 4卷 / 1期

关键词：

Amenorrhea; Inhibin; Turner Syndrome; Premature Ovarian Failure; White Matter Abnormality;

D O I：

10.1186/1472-6874-4-8

中图分类号：

学科分类号：

摘要：

Background: Premature Ovarian Failure (POF), defined as the development of hypergonadotropic amenorrhea before the age of 40 years, occurs in about 1% of all women. Other than karyotype abnormalities, very few genes are known to be associated with this ovarian dysfunction. Recently, in seven patients who presented with POF and white matter abnormalities on MRI (ovarioleukodystrophy) eight mutationswere found in EIF2B2, 4 and 5. Methods: To further test the involvement of known mutations of EIF2B genes in POF, we screened 93 patients with POF who did not have identified leukodystrophy or neurological symptoms. We evaluated these eight mutations and two additional mutations that had been found in patients with milder forms of eIF2B-related disorders. We used restriction enzymes and direct sequencing. Results: None of the known mutations in EIF2B genes, either homozygous or heterozygous, were identified in our 93 patients with pure 46,XX POF. The upper 95 % confidence limit of the proportion 0/93 is 3.2%. Conclusions: We conclude that eIF2B mutations, already described in cases of POF associated with white matter abnormalities, are an uncommon cause of pure spontaneous premature ovarian failure. © 2004 Fogli et al; licensee BioMed Central Ltd.

引用

页数：4

共 11 条

[1]

Coulam C.B., Adamson S.C., Annegers J.F., Incidence of premature ovarian failure, Obstet. Gynecol., 67, pp. 604-606, (1986)

[2]

Shelling A.N., X chromosome defects and premature ovarian failure, Aust. NZ J. Med., 30, pp. 5-7, (2000)

[3]

Conway G.S., Premature ovarian failure, Curr. Opin. Obstet. Gynecol., 9, pp. 202-206, (1997)

[4]

Schlessinger D., Herrera L., Crisponi L., Mumm S., Percesepe A., Pellegrini M., Pilia G., Forabosco A., Genes and translocations involved in POF, Am. J. Med. Genet., 111, pp. 328-333, (2002)

[5]

Shelling A.N., Burton K.A., Chand A.L., van Ee C.C., France J.T., Farquhar C.M., Milsom S.R., Love D.R., Gersak K., Aittomaki K., Winship I.M., Inhibin: A candidate gene for premature ovarian failure, Hum. Reprod., 15, pp. 2644-2649, (2000)

[6]

Aittomaki K., Lucena J.L., Pakarinen P., Sistonen P., Tapanainen J., Gromoll J., Kaskikari R., Sankila E.M., Lehvaslaiho H., Engel A.R., Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure, Cell, 82, pp. 959-968, (1995)

[7]

Latronico A.C., Anasti J., Arnhold I.J., Rapaport R., Mendonca B.B., Bloise W., Castro M., Tsigos C., Chrousos G.P., Brief report: Testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene, N. Engl. J. Med., 334, pp. 507-512, (1996)

[8]

Harris S.E., Chand A.L., Winship I.M., Gersak K., Aittomaki K., Shelling A.N., Identification of novel mutations in FOXL2 associated with premature ovarian failure, Mol. Hum. Reprod., 8, pp. 729-733, (2002)

[9]

Fogli A., Rodriguez D., Eymard-Pierre E., Bouhour F., Labauge P., Meaney B.F., Zeesman S., Kaneski C.R., Schiffmann R., Boespflug-Tanguy O., Ovarian Failure Related to Eukaryotic Initiation Factor 2B Mutations, Am. J. Hum. Genet., 72, pp. 1544-1550, (2003)

[10]

Fogli A., Wong K., Eymard-Pierre E., Wenger J., Bouffard J.P., Goldin E., Black D.N., Boespflug-Tanguy O., Schiffmann R., Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus, Ann. Neurol., 52, pp. 506-510, (2002)

← 1 2 →